Evaluation of antiviral drug synergy in an infectious HCV system.

about

Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle.Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.

P2860

Q40151324-B7E14557-1258-45F7-B1B2-5654229813B5 Q47548651-4C994DDE-1FDC-425E-AF03-D84DC61EB7EB

P2860

Evaluation of antiviral drug synergy in an infectious HCV system.

Item

http://www.wikidata.org/entity/Q39871877

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Evaluation of antiviral drug synergy in an infectious HCV system.

@en

Evaluation of antiviral drug synergy in an infectious HCV system.

@nl

type

Item

label

Evaluation of antiviral drug synergy in an infectious HCV system.

@en

Evaluation of antiviral drug synergy in an infectious HCV system.

@nl

prefLabel

Evaluation of antiviral drug synergy in an infectious HCV system.

@en

Evaluation of antiviral drug synergy in an infectious HCV system.

@nl

P1476

Evaluation of antiviral drug synergy in an infectious HCV system.

@en

P2093

Billy Lin

http://www.w3.org/2001/XMLSchema#string

Hyung Joon Yim

http://www.w3.org/2001/XMLSchema#string

Shanshan He

http://www.w3.org/2001/XMLSchema#string

T Jake Liang

http://www.w3.org/2001/XMLSchema#string

Zongyi Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclosporin A associated helicase-like protein facilitates the association of hepatitis C virus RNA polymerase with its cellular cyclophilin B

The SH3 binding motif of HCV [corrected] NS5A protein interacts with Bin1 and is important for apoptosis and infectivity

Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry

Hepatitis C.

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Current and future therapies for hepatitis C virus infection.

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.

P304

595-603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3851/IMP3044

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27035622

http://www.w3.org/2001/XMLSchema#string

P932

5580926

http://www.w3.org/2001/XMLSchema#string

Evaluation of antiviral drug synergy in an infectious HCV system.

about

P2860

P2860

Evaluation of antiviral drug synergy in an infectious HCV system.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932